Roche reaps promising results in Ph2 asthma study

Roche says that its experimental asthma drug, the IL-13 blocking antibody lebrikizumab, proved promising in a mid-stage clinical trial. Researchers said that the drug spurred in a "statistically significant increase in FEV1 (measure of lung function) in adults with asthma whose symptoms were inadequately controlled with inhaled corticosteroids." The results were published in the New England Journal of Medicine. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.